Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:CADL

Candel Therapeutics Q3 2026 Earnings Date & Estimates

Candel Therapeutics logo
$8.92 -0.15 (-1.63%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Candel Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Candel Therapeutics in Q3 2026

Candel Therapeutics is expected to post earnings of -$0.3468 per share. In the same quarter a year earlier Candel Therapeutics reported -$0.21 per share. Candel Therapeutics last reported on August 13, 2026, posting -$0.52 per share and missing the -$0.2379 consensus estimate. Candel Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3468
Prior-Year EPS
-$0.21

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.52 (Missed by -$0.2821)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Candel Therapeutics Q3 2026 Earnings FAQ

Candel Therapeutics (NASDAQ:CADL) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Candel Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Candel Therapeutics to post earnings of -$0.3468 per share for Q3 2026.

Candel Therapeutics Earnings Headlines

Candel Therapeutics Inc (CADL)
October 4, 2026  |  in.investing.comhttps://in.investing.com/equities/candel-therapeutics-news/2
Candel Therapeutics, Inc. (NASDAQ:CADL) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084343
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 15 at 1:00 AM  |  Base Camp Trading (Ad)
Candel Therapeutics, Inc. Announces Publication Of Final Phase 2a Clinical Trial Results Of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC
October 3, 2026  |  marketscreener.comM
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373373/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
See More Candel Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage biopharmaceutical company focused on developing biological immunotherapies designed to stimulate and strengthen the body’s immune response against cancer. The company’s approach uses engineered viruses intended to selectively target tumors and activate broader antitumor immunity.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy being developed for high-grade glioma, including recurrent glioblastoma. The company is also developing CAN-2409, a non-replicating adenovirus-based therapy designed to work with a prodrug to trigger localized cancer-cell destruction and immune activation. These programs are being evaluated in clinical studies for solid tumors.

The company’s discovery efforts are supported by its enLIGHTEN™ platform, which uses genomic and computational tools to identify and develop new viral immunotherapies. Candel conducts its research and clinical-development activities primarily through networks in the United States and other locations where its clinical studies are conducted. Paul Peter Tak, M.D., Ph.D., has served as the company’s chief executive officer and is also associated with its leadership and strategic direction.

View Candel Therapeutics Profile
Earnings Tools